News

Results from Phase 1 of the “Blueprint PD-L1 IHC Assay Comparison Project"

 

Media Contact: Becky Bunn                                                                        Adam Mohrbacher   
IASLC Communications Projects Specialist                                               IASLC Content Specialist
Becky.Bunn@IASLC.org | 720-254-9509                                                Adam.Mohrbacher@IASLC.org | 720-598-1943

Results from Phase 1 of the “Blueprint PD-L1 IHC Assay Comparison Project"

Today the JTO, the official journal of the IASLC, published “PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the “Blueprint PD-L1 IHC Assay Comparison Project”. The IASLC has taken a leadership role in this important industrial-academic partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC assays. Read the entire article here.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.

###

November 30, 2016